This relationship will provide Duke investigators access to the company’s core technologies, Laser Capture Microdissection and Reverse phase Protein Microarray. The proprietary combination of these technologies provides a
The study was a randomized, double-blind, placebo-controlled, cross-over, single-rising dose study conducted with healthy male volunteers. Objectives of the study included assessments of the safety, tolerability, and pharmacokinetics
These devices facilitate manual x-ray contrast media injections during angiography procedures performed in the cardiac catheterization laboratory and interventional radiology suite. Under the terms of the agreement, Covidien
In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has
In the private placement, Sonomax intends to issue a maximum of 13,333,333 units at a price of $0.15 per unit, for maximum proceeds to Sonomax of $2 million.
The $35 million investment represents the second major investment in ProCure by McClendon Venture Company (MVC) and pushes the firm’s total investment in the growing proton therapy treatment
As part of the R&D funding for Kevetrin, the company has completed a $400,000 9% secured convertible debenture financing. The debentures and concomitant interest come due December 1,
Sirtex received an investigational device exemption from the FDA to conduct the trial. The trial is actively recruiting patients at Thomas Jefferson University’s Kimmel Cancer Center in Philadelphia,
ActoGeniX’s lead product AG011 is an ActoBiotic for treatment of inflammatory bowel disease and has previously been successfully tested in a Phase I clinical trial with Crohn’s disease
The patent covers three main ways of associating the nanoparticles with filter media – having pellets of nanoparticles located adjacent to the filter media, coating the filter media
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.